Boan Biotech (6955.HK) today announced that a Phase 3 clinical trial (a comparative study of efficacy and safety) for its Aflibercept Intravitreous Injection (BA9101) in China has been completed. The ...
Boan Biotech (6955.HK) today announced its 2023 financial results and latest developments.High-quality development delivering remarkable performanceDuring the reporting period, the company's reven...
Yantai, March 8, 2024 – Boan Biotech (6955.HK) today announced the completion of a Phase 3 clinical trial (a comparative study of efficacy, safety, and immunogenicity) for its Dulaglutide Inject...